-

Aurinia Announces Results of the 2021 Annual General Meeting

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.

Detailed results of the vote by proxy for the election of directors are provided below:

Nominee

     

Votes For (%)

     

Votes Withheld (%)

George M. Milne

     

80.91

 

 

 

19.09

Peter Greenleaf

     

92.18

 

 

 

7.82

David R.W. Jayne

     

93.00

 

 

 

7.00

Joseph P. Hagan

     

87.15

 

 

 

12.85

Daniel G. Billen

     

95.64

 

 

 

4.36

R. Hector MacKay-Dunn

     

93.27

 

 

 

6.73

Jill Leversage

     

95.05

 

 

 

4.95

Timothy P. Walbert

     

89.56

 

 

 

10.44

In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Contacts

Investors:
Glenn Schulman, PharmD, MPH
Investor Relations & Corporate Communications, Aurinia
gschulman@auriniapharma.com

Media:
Dana Lynch
Corporate Communications, Aurinia
dlynch@auriniapharma.com

Industry:

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH
Release Versions
English

Contacts

Investors:
Glenn Schulman, PharmD, MPH
Investor Relations & Corporate Communications, Aurinia
gschulman@auriniapharma.com

Media:
Dana Lynch
Corporate Communications, Aurinia
dlynch@auriniapharma.com

More News From Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, respectively, from $67.8 million and $175.3 million, respectively, for the same periods of 2024. Net Pro...

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia’s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A...

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025...
Back to Newsroom